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ABSTRACT

ESTIMATING CUMULATIVE INCIDENCE RATE ON INTERVAL
CENSORED DATA IN AN ILLNESS-DEATH MODEL
Chen Qian
March 31, 2021
Phase IV clinical trials are designed to monitor long-term side effects caused over
time by the medical treatment. For instance, in advanced primary cancer treatment,
childhood cancer survivors are often at risk of developing undesired events, such as
cardiotoxicity, during their adulthood. Such problems could be due to their cancer or
the treatment they received for their cancer such as radiation or intensive chemotherapy.
Cardiotoxicity can be diagnosed with electrophysiology with measurements of
fraction shortening, afterload, etc. Often the primary focus of a study could be on
estimating the cumulative incidence (CI) of a particular outcome of interest such as
cardiotoxicity. However, it is not possible to evaluate patients on a continuous basis
and often this information is collected through cross-sectional surveys by following
patients longitudinally. This leads to interval censored data since the exact time of
the onset of toxicity is not known.
This dissertation consists of three projects related to the estimation of cumulative incidence rates on interval censored data in an illness-death model. In the
first project, missing observation problem in the current status data is discussed. An
imputation method is proposed to handle such issue. The second project introduces
v

a new method for estimating transition intensity probabilities using semi-parametric
with EM (expectation-maximization) approach in a special case two-state model. A
logit relationship for the treatment intensities in the two groups is proposed. In the
third project, the cumulative incidence rates are evaluated using the maximum likelihood estimation approach in a complete three-state illness-death model in which
death is incorporated as competing risk.
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CHAPTER 1
INTRODUCTION
This dissertation will focus on estimating fixed-term cumulative incidence rates in
an illness-death model. Figure 1.1 provides a visualized overview of the model. The
target population in our research is childhood cancer survivors treated with anthracycline chemotherapy and/or thoracic irradiation. The methodology can be extended
to other types of interval censored data as well. Cancer survivors are alive and have
not developed cardiac abnormality at the initial state (state 1). They can either be
diagnosed cardiac abnormality at the follow up (state 2) or reach the terminal state
directly with or without cardiac failure (state 3). For patients at state 2, they can
either remain at the current state when the data is observed or reach the terminal
state. Note that for patients at state 2, the actual onset times u of these events
prior to the current status are unknown. Cardiac abnormality can occur any time
between state 1 and state 2. In this dissertation, our primary interest is on estimating
the transition intensity rate λ1 (u). This will provide valuable information and help
evaluate the side effects of the treatment in the long run.

1.1 Imputing Partial Status and Estimating Incidence Rate in an
Illness-death Model with Application to a Phase IV Cancer Trial
The first project mainly focuses on the missing observation problem in the current
status data. One such study was designed by Hudson et al. (2007) to study the
effect of anthracyclines exposure, received as part of treatment for childhood cancer,
1

to cardiotoxicity. Rai et al. (2013) utilized a parametric approach for assessing the
effect of anthracycline on the cumulative incidence of cardiotoxicity but excluded the
patients with missing information. In this project, we resort to impute the missing
current status using the regression method in an illness-death/failure model. A comprehensive simulation study suggests that the results obtained using the imputation
approach are significantly more efficient than those obtained without imputation. We
further apply the proposed approach to the data reported in Rai et al. (2013) and
compare the results reported there to our approach that utilizes imputation.

1.2 Estimating Transition Intensity Rate on Interval Censored Data
using Semi-parametric with EM Algorithm Approach
Rai et al. (2013) computed the transition intensity rate using parametric approach
through the maximum likelihood estimation in a special case illness/death model.
The anthracycline effect was calculated using the difference of likelihood ratio test.
However, the parametric approach may not be suitable if the underlying parametric
assumptions do not hold. In the second project, we propose a semi-parametric model,
with logit relationship for the treatment intensities in the two groups, to compare the
treatment effects within the context of illness-death model. The estimation of the
parameters is done using EM algorithm with profile likelihood. Results from simulation studies suggest that the semi-parametric model with EM algorithm approach is
practicable and comparable to the parametric model.

2

1.3 Estimating Cumulative Incidence Rate on Interval Censored Data
in an Illness-Death Model
In the third project, a new dataset is being used, which is an updated version of the
first data that was discussed in the first project. Since the follow up time is much
longer, a handful of death cases have occurred. Follow Rai et al. (2013)’s methodology
on two-state models, we extend the application to a complete three-state illness/death
model. We resort to incorporate death as competing risk and calculate the cumulative
incidence rates using the maximum likelihood estimation approach.

3

1.4 Figures
Figure 1.1: Three-state illness-death model.
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CHAPTER 2
IMPUTING PARTIAL STATUS AND ESTIMATING INCIDENCE
RATE IN AN ILLNESS-DEATH MODEL WITH APPLICATION
TO A PHASE IV CANCER TRIAL

2.1 Introduction
2.1.1 Background
As a result of more modern therapies and better supportive care, the 5-year survival
rate for childhood cancer has improved significantly and currently exceeds 80% (Armstrong et al., 2016; Howlader et al., 2015; Phillips et al., 2015; Fidler et al., 2016).
In 2011 there were 390,000 survivors of childhood cancer living in the US and it is
expected that by 2020 there will be more than 500,000 childhood cancer survivors
(Robison and Hudson, 2014). This improvement in survival rate comes at a price
as these survivors are at an elevated risk of experiencing long-term morbidity and
early mortality as a result of their cancers and its treatment. The purpose of Phase
IV clinical trials is to monitor long-term sequela and develop interventions to mitigate their effect in long-term. A chemotherapy agent Anthracycline has served as
the backbone for many pediatric malignancies because of its therapeutic effects, but
it is also well known to be cardiotoxic (Krischer et al., 1997; Sorensen et al., 2003).
One such study was undertaken by Hudson et al. (2007) to evaluate the effect of
anthracycline exposure on cardiotoxicity using non-invasive modalities.
Cardiotoxicity is the occurrence of heart electrophysiology dysfunction or/and
5

muscle damage. The heart is too weak to pump and circulate blood. There are many
measures of electrophysiology dysfunction or/and muscle damage, including shortening fraction, afterload, ejection fraction, etc. (Hudson et al., 2007; Sorensen et al.,
2003; Pein et al., 2004). Just like many other types of disease, it is not possible to
evaluate patients very often to estimate the onset time of cardiotoxicity partially due
to economic concerns. The incidence rates are therefore difficult to estimate. Usually,
patients are followed longitudinally in the clinics, but not all follow a routine pattern.
Hence, it is convenient to design cross-sectional surveys for estimating the effect of
long-term side effect of treatments and its predictors. We only know the current status of the patient with onset prior to current status, but not the actual onset times
of these events. These types of incomplete data are referred to as interval censored
data since the actual onset time of the events are unknown (Rai et al., 2013; Krischer
et al., 1997; Sorensen et al., 2003; Pein et al., 2004; Sun, 2006) and our interest is in
the estimation of the onset rate or the cumulative incidence rate.
Nonparametric procedures for analyzing interval censored failure time data
have been extensively studied and discussed in the literature (Sun, 2006; Ayer et
al., 1955; Van Eeden, 1956; Peto, 1973; Turnbull, 1976). Another issue in the crosssection survey study is that results need to be generalized to the specific population.
There can be competing toxic effects from the same drug. In this paper, we have the
same interest, as Rai et al. (2013), in estimating the cumulative incidence rates using
a parametric approach, but focus on improving the accuracy by imputing the missing
observations using multivariable regression method.
In practice, most investigators exclude observations with missing values and
incomplete cases. Despite its simplicity as using only complete cases, it may lose
the important information in the incomplete cases and ignore the possible systematic
differences between the complete and incomplete cases. Hence, the resulting inference may not be applicable to the population of all cases, especially with a smaller

6

number of complete cases. It is well known that imputation is a widely used method
for handling missing data. Little and Rubin (2002) and Buuren (2012) provided an
excellent overview of the methods for conducting analyses with missing data. Further information on multiple imputations can refer to Rubin (1987, 1993), and Rubin,
Stern, and Vehovar (1995) which discussed imputation of missing discrete data. King
et al. (2001) reviewed many of the practical costs and benefits of multiple imputations. For routine imputation of missing data, Schafer (1997) presented a method
based on multivariate normal distribution. Liu (1995) used the t distribution, and
Van Buuren, Boshuizen, and Knook (1999) used interlocking regressions. Furthermore, Troxel, Ma, and Heitjan (2004) presented a method to study the sensitivity of
inferences to missing-data assumptions.
This chapter is organized as follows. In the following subsection, we provide
the details of the motivating example to introduce the problem. In the Methods section, we give a brief description of the procedure introduced in Rai et al. (2013) and
construct corresponding likelihood functions. The data from the motivation example
is analyzed by imputing the missing values and compared with the results obtained
without imputation in the Results section. An extensive simulation experiment to
study the performance of the imputation approach are summarized as well. The
Discussion section is devoted to miscellaneous remarks.

2.1.2 Motivation Example
A study was undertaken by Hudson et al. (2007) to evaluate the effect of anthracycline
on cardiotoxicity using 12-lead ECG and echocardiography, non-invasive technique.
In the study, the cancer survivors were recruited from St. Jude Children’s Research
Hospital After Completion of Therapy Clinic. The survivors were classified into two
groups; the first group consisted of survivors that received cardiotoxic therapy (anthracycline and/or thoracic radiation) and the other group did not receive cardiotoxic

7

therapy (no anthracycline nor thoracic radiation). The details of the study can be
found in Hudson et al. (2007). The study was approved by the institutional review
boards at St Jude Children’s Research Hospital and Stanford University (Stanford,
CA). All study participants or their parents provided informed consent. Survivors
with cardiotoxic therapy were designated as At-Risk (AR) and those without cardiotoxic therapy as Not At-Risk (NR).
One-time clinical assessment was made by the primary oncologists to identify
the survivors with signs of heart failure using New York Heart Association classification. Along with the clinical evaluation, non-invasive testing based on 12-lead ECG
and echocardiography were conducted within 24 hours of the clinical assessment.
In this project, the outcome variables we used are afterload (AF) and fractional shortening (FS). A short summary about the cohort is summarized in Table
2.1. Further description is available in Hudson et al. (2007). Detailed explanation
of a similar motivation example can be found in Rai et al. (2013). On closer examination of the data, it was seen that there were missing data in outcome measures
AF and FS. A total of 40 survivors had missing AF values and 6 of those were also
missing FS values. To keep the discussion simple and straightforward these 6 observations were deleted from our analysis and our attention was paid to imputing 34
missing AF observations. Although, the imputation approach discussed could easily
be applied to data missing with several variables in a recursive manner. The scatter
plot of AF and FS displayed in Figure 2.1 does not show any clear missing pattern;
the missing values of AF are in the entire range of values of FS. Also note that the
missing proportion of AF values in the NR (7/54 = 13%) and AR (27/218 = 12%)
were almost identical.
In this study, echocardiography was performed as a research measure and not
in response to clinical symptoms. Individuals with previously established cardiac
disease were excluded from participation. As formally assessed by New York Heart
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Association classification, none of the study participants reported clinical symptoms
of cardiac dysfunction at enrollment. The imaging quality in echocardiography is
dependent on obtaining a clear acoustic window from which ventricular volumes are
estimated based on geometric assumptions. Operator experience and variations in
thoracic structures can contribute to difficulties in obtaining technically satisfactory
data in a given study. These factors randomly contributed to missing data among
study participants. AF is not a standardly used assessment in clinical practice, thus,
despite training of ultrasonographers for this study, this factor may have contributed
to a higher prevalence of missing AF measurements compared to FS. In other words,
AF is either under detected or over detected, but operators might miss it, and therefore, causing missing values. Thus, we feel that there is no selection bias related to
those with and without abnormal FS and AF identified as part of the study. The
missing values of AF are displayed in Figure 2.1, also do not show any pattern.
A crude approach to estimating the incidence rates and obtaining confidence
intervals is to use the Kaplan-Meier estimator with the assumption of the evaluation
time as the onset time. Then, the incidence rate of each type of toxicity is estimated.
Some of these toxicity measures could be missing. In this project, we impute the
missing measurements using a regression method first and then use a parametric approach to estimate incidence rates of specific toxicity. For the cardiotoxicity data,
the 34 missing AF values were imputed using a multivariable regression with FS and
other covariates, such as age, diagnosis, risk status, BMI as predictors. The estimates
of cumulative incidence rates were derived based on the data after imputation and
then compared with those derived in Rai, et al. (2013) without imputation.

9

2.2 Method
2.2.1 Cardio-Measures Abnormality Model
The descriptive statistics of all participants can be found in Table 2.1. Detailed cardiomeasures abnormality model can be found in Rai et al. (2013). The general theory
for a cross-sectional data with indicators of cardiac abnormality and death/cardiac
failure, and time since the treatment to the survey or the death/cardiac failure, as
depicted in Figure 1.1, can be found in Rai et al. (2013) as well. We also assume
that cardiac abnormality is irreversible and is the precursor for cardiac failure.
Rt
We are interested in estimating Λ1 (t) = 0 λ1 (u) du, the cumulative incidence
function (CIF), but focus on the comparison of CIFs between AR and NR groups
based on the original data and imputation data. λ1 (u) is the transition intensity for
patients progress from state 1 to state 2.
Table 2.2 identifies the various types of observations which occur in this illnessdeath/failure model and the corresponding contribution to the likelihood, denoted as
L1 (t) to L4 (t), which are functionals of intensities and pseudo-survival functions. The
approach of the likelihood functions can be found in Appendix 1. Rai et al. (2013)
derive the explicit form of L1 (t) to L4 (t) for both constant and piecewise exponential
models and the likelihood functions. X(t) represents the state that the patient is
current occupying. Q(t) represents the probability that the time to the first event
exceeds t.

2.2.2 Imputation Model
Let the cardiac measure, such as AF, be denoted byY. Assume that Y = (Y1T , Y2T )
be a n×1 response vector with Y1 (n1 × 1) observed and Y2 (n2 × 1) missed, and
X = (X1 , X2 ) be corresponding n × p matrix comprised of covariates including other
cardiac measures (other response variables).
10

There are several methods for imputation which can be broadly classified as
single imputation or multiple imputation (MI). In the MI approach several copies
of the complete data set are created and then the appropriate statistical method is
applied to each data set and the results from these analyses are then combined to
provide the final results. Usually, MI approaches are preferred over single imputation
as they incorporate variability due to imputation (Burren, 2002; Molenberghs and
Fitzmoaurice, 2009; Kenward and Carpenter, 2009). There are many MI approaches
discussed in literature, but two most commonly used approaches based on joint multivariate modeling or fully conditional specification perform quite well in the regression
setting, cited in Huque et al. (2018). It may be noted that PROC MI can perform
imputations for data that have monotone or arbitrary missing patterns. PROC MI
with FCS option, a standard feature in SAS version 9.4 (SAS Institute, Cary, NC),
utilizes the conditional distribution and can incorporate both continuous and categorical variables appropriately, see Liu and De (2015). In our setting, we had missing
values only in AF and we wanted to take advantage of the relationship between AF
and other covariates of interest that included categorical variables. Therefore, we
preferred to perform the imputations using PROC MI in SAS with FCS option. The
method can be briefly described as follows:
A multivariable regression model y = xβ +  is fitted based on the complete data Y1 and X1 , and the least squared estimator β̂ of β (p × 1) and associated
variance-covariance matrix is obtained. Then, missing values in Y2 are imputed using
the posterior predictive distributions, see PROC MI in SAS (SAS Institute, Cary,
NC) for details. It is natural to use the imputation data (Y1 , Yˆ2 )T instead of only Y1
and is anticipated that the imputed information in Yˆ2 will improve the related results
in statistical analysis.
To each complete data set, the likelihood ratio test was applied to compare
the two risk groups (AR and NR). In the regression framework, one could use PROC
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MIANALYZE in SAS to combine the results from multiple imputations to conduct inference that incorporates inherent variability introduced due to imputations (Burren,
2002; Molenberghs and Fitzmoaurice, 2009; Kenward and Carpenter, 2009). However, in our setting, p-values associated with each imputation are obtained based on
the likelihood ratio test. Then, the overall conclusion can be drawn from some types
of summary measure for all the p-values such as mean or median. We prefer to report
the results based on median as that would be much more robust than mean.

2.3 Result
2.3.1 Application: Cancer Survivor Study
In this section, we obtained the imputed data for the cardiotoxicity example and applied the theory for the exponential model (detail can be found in the third project)
to evaluate the effect of anthracyclines on cardiotoxicity. Furthermore, the results
obtained using the imputation approach were then compared with those obtained
without imputation, reported in Rai et al. (2013), under the assumption of no
deaths/cardiac failures. The simplest model is the Parameter-1, which is a one parameter Exponential model. Normally cardiotoxicity would not occur within five years of
cancer treatment. Based on this consideration, we also fit two piecewise Exponential
models. Parameter-2, based on two incidence rates in which the first one represents
up-to year five and the second one represents year 5 and above, and Parameter-3,
based on three incidence rates: up-to year 5, between year 5 and year 10, year 10 and
above (see Figure 2.2 for a general idea).
In the cardiotoxicity example, there are 278 subjects, Leukemia (n=77), Sarcoma (n=74), Lymphoma (n=56) and Embryonal (n=71), and 34 measurements were
missing for AF and 6 were missing in both measurements AF and FS, but no covariate
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information was missing. We exclude the 6 with both missing. Hence, we have 272
subjects and employ the multivariable regression method to estimate the 34 missing
measurements in AF based on the values of FS and corresponding covariates, like
age at diagnosis, race, gender, BMI, QTC, diagnosis group and risk group (AR/NR)
(Henry, Gardin and Ware, 1980; Colan et al., 1992). Based on 4 diagnosis groups, we
define three dummy variables as follows:

Diag1 =




1 Leukemia


0 Otherwise

, Diag2 =




1 Sarcoma


0 Otherwise

, Diag3 =




1 Lymphoma

.



0 Otherwise

Before conducting the regression analysis, the Shapiro-Wilk test of normality was applied to original AF and FS measurements and a few commonly used
transformations for making the underlying distributions of AF and FS more normal.
Log(AF) was normally distributed (p=0.701), but original AF (p<0.001) was not.
On the other hand, Log(FS), Logit(FS) and FS were not normally distributed with
p values <0.001, 0.007 and 0.026, respectively. This suggests fitting the regression
model using logarithm transformation of AF and original FS. The significant predictors with coefficients, their p-values and R2 in the model are presented in Table 2.3.
That is,

log(AF ) = 5.534−3.891 F S+0.008 Age+0.081 Risk+0.098 Diag2−0.010 BM I+ (1.1)

where Risk=1 for patient in AR group and 0 in NR group. Based on the regression
model, the values of FS and the covariates, the 34 missing AF values are imputed.
Thus, after imputing the missing values the total sample size is 272.
Because AF is the only variable with missing values in our data (n=272),
we consider the data including age at diagnosis, BMI, diagnosis group, risk group,
FS. Based on each imputation data, we calculate the Cumulative Incidence Function
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(CIF) for constant exponential model, two or three piecewise exponential models
using the method. Then, the methods were applied to the imputed data sets for each
group, AR and NR, and both groups combined. Then, based on the likelihood ratio
test, the corresponding p-value for group effect for the variable AF is 0.014 (median
of m=20 imputations). On the other hand, the p-value without imputation is 0.020
(Rai et al., 2013). The results with imputation seem to be little bit more sensitive
for the group effect in AF compared to that without imputation. Note that not using
the illness/death model as proposed and, instead, using logistic regression, without
imputation, the group effect was only marginally significant (p=0.065) (Hudson et
al., 2007; Rai et al., 2013). Thus, the approach based on illness/death model led
to a better understanding of this data and motivated the current development. A
summary of the results is given in Table 2.4. The cumulative incidence function
(CIF) was derived for exponential and piecewise exponential models for the imputed
data using the above regressions model and SAS procedure (PROC MI, with m=5,
10 and 100 imputations) when compared to those based on the original data (without
imputation).
In Table 2.4, the group effects are reported for both data without imputation
and with imputation for m=5, 20 and 100. For imputed data, we reported the pvalues of group effect as mean, minimum, maximum, and median. A comparison of
cumulative incidence rates can be found in Figure 2.3.

2.3.2 Simulation Study
To assess the performance of the imputation approach we conducted simulation studies as described below.
The primary focus is on assessing the performance of imputing AF in Anthracycline Cardiac Toxicity data for comparing the cumulative incidences of cardiac
toxicity in the illness-death model as discussed above. The detailed steps are de-
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scribed as follows.

Step 1: From Table 2.3 it is clear that log(AF) values are associated with the risk
group (AR and NR), diagnosis group (Sarcomas vs. others), Age, FS, and BMI and
using the equation (1.1) we first filled all the missing values of AF with the mean
predicted values and obtained a complete copy of the data set.

Step 2: Then, for simulation studies we first created four subgroups:
Group 1: The patients which are in AR group diagnosed with Sarcomas (sample size
n1 ).
Group 2: The patients which are in AR group diagnosed with other cancers (sample
size n2 ).
Group 3: The patients which are in NR group diagnosed with Sarcomas (sample size
n3 ).
Group 4: The patients which are in NR group diagnosed with other cancers (sample
size n4 ).
Now to keep the covariance structure consistent with the observed data the sample
mean and variance-covariance matrix were obtained for the variables LAF=log(AF),
FS, Age, BMI and LTime=log(Time), where Time is the length of follow-up from
diagnosis to the time of survey and the individual can be in one of the three states
as shown in Figure 1.1.

Step 3: (Generate multi-normal data by group): Generate a sequence of random vectors, (LAF, F S, Age, BM I, LT ime)j , j = 1, . . . , ni , from multi-normal distribution for Group i (i = 1, 2, 3, 4). That is, we assumed that,

(LAF, F S, Age, BM I, LT ime)j ∼ i.i.d. M V N (vi , Σi ) f or j = 1, 2, . . . , ni , i = 1, 2, . . . , 4,
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where n1 = n2 = n/3 and n3 = n4 = n/6 for n = 180, 240, or 300 (the sample sizes
for three simulation studies) and vi and Σi are the sample mean vector and covariance matrix. In this simulation study we used unequal samples size to reflect higher
proportion of At-risk survivors in our cohort.
Note: We noticed the means of FS and LAF were significantly low (high) for Group
1, which would have led to highly significant p-values for comparing the two groups
(AR vs. NR). Therefore, we adjusted the mean values for these two variables in the
simulation studies as follows:

Step 4: (Incomplete Data in AF): From the sample size generated in Step 2,
we randomly deleted R% (R=20 or 30) of AF values, and got incomplete data with
sample sizes (100-R)% n.

Step 5: (Imputed data): Using SAS procedure PROC MI with FCS option we
imputed AF values and obtained a complete copy of the data set.

Step 6: (Calculate p-value for group effect): For the one parameter exponential
distribution, the p-values for group effect (comparing AR with NR) were obtained
using the likelihood ratio test for complete (originally generated), incomplete and
imputed data set.
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Step 7: The imputation process (Step 5) was repeated 20 times to obtain 20 copies
of complete data sets, which resulted in 20 p-values. A description of the p-values in
terms of mean, median, minimum, and maximum is summarized in Tables 2.5-2.7.

Step 8: Steps 2 – 7 were repeated 10 times to assess the performance of the imputation approach on 10 independently generated data sets. Simulation results are
presented in Tables 2.5-2.7.

From Tables 2.5-2.7, it is seen that, in general, the median of the p-values
is much closer to the p-value obtained from the complete data compared to those
obtained from the incomplete data. However, there are some extreme situations
where the results from the complete data and those obtained from imputations and
incomplete data are not in agreement and this could be due to chance that more
observations were deleted from a particular group and the regression is not able to
completely exploit the underlying correlation structure. For example, for the 4th simulation, when the sample size is 180 and 30% of the observations are imputed the
p-value for the complete data set is 0.007, but those corresponding to incomplete
data and imputed data were 0.059 and 0.469, respectively. This clearly suggests that
the manner in which data are generated and the observations are randomly deleted
might have changed the underlying structure particularly those who are in the AR
and NR groups. However, for lager sample size (n=300) we see that in all simulations the median p-value based on imputation is much closer to the p-value obtained
from the complete data. Thus, it is clear that with imputation approach we are able
to exploit the underlying correlation structure and obtain nearly unbiased conclusions.
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2.4 Discussion
In this paper, we have employed the illness/death model developed in Rai et al. (2013)
and demonstrated an example by imputing the missing observations in a Phase IV
current status data. Though the methodology has been applied on a parametric
model, it can be easily extended to other models under different settings. Clinical
data are usually analyzed using meanly log rank test or Kaplan Meier curves due to
its simplicity (Kaplan and Meier, 1958). However, in the setting of interval censored
data the approach proposed here is simple to use and can be implemented easily to
estimate fixed-time cumulative incidence function with or without imputation (Rai
et al., 2013).
In order to monitor the long-term effects of the cancer treatment, the longitudinally followed patients are evaluated multiple times throughout their adulthood. At
every visit multiple health indicators are measured and recorded. Besides from cardiotoxicity, other events such as obesity and secondary cancer might have occurred.
Some of these events can be identified as competing risk while other events might be
correlated to the variables we are interested in. This leads to multivariate time-toevent data. In our example, cardiotoxicity can be determined by looking at abnormal
AF and FS values, but there are some other measures to evaluate cardiotoxicity such
as systemic vascular resistance (SVR). For some reasons, not all patients had both
measures. Based on bi-variate assumption, the model would only include subjects
that have valid information on both outcomes and this would reduce the sample size
and potentially ignore important information. Based on this consideration, the multivariable regression method was used to impute the missing observations and to apply
the parametric method to the imputed data and compare the results with those obtained without imputation.
As stated before, the problem of evaluating possible toxic effects of cancer ther-
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apies in a Phase IV trial setting is an important problem. Among the many issues in
such studies, missing data is a key aspect that can influence the inferences. It is also
important to understand the nature of impact of missing data on the analysis and the
interpretation of the study data. Also note that imputation increases the sample size,
and thus increases statistical power to detect the same effect size, but if the model
assumptions are not correct, the inference may not be valid. Thus, it is recommended
to report the p-values with and without imputation. However, with higher absolute
correlations between two outcome measures (the primary outcome measure, AF, with
higher missing and the secondary outcome measure, FS, with little or no missing),
produced efficient results, a rigorous simulation study with different amount of correlations between two outcome measures, amount of missing and model uncertainty
is underway to consider this aspect and will be reported elsewhere; this is along the
lines for our work of a randomized clinical study (Liu and De, 2015).
Another limitation of this study is that, this is a cross-sectional survey to estimate the long-term effect of cardiotoxicity of the primary treatment of cancer. Dodge
(2003) defined cross-sectional survey “A method of data collection whereby a battery
of questions is asked of participation at one single point or in a relatively small interval of time. Inferences about a population must be anchored to the time period in
which the sample was taken. Data from cross-sectional surveys are typically unable
to be used to prove the existence of cause-and-effect relationships.” Even though, this
is based on enrolling consecutive eligible patients in a very homogeneous environment
(St. Jude Children’s Hospital treats patients without charge to patients), the effect
of this limitation is minimized, but cannot be reduced to zero. Generalization of the
results to a general population should be done with caution.
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2.5 Tables and Figures
Figure 2.1: Scatter plot of AF and FS within AR and NR group of patients. Complete
data (labeled c) displays strong correlation between AF and FS. Missing values of AF
are in almost the entire range of FS values (labeled m).
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Figure 2.2: Piecewise Incidence Rate.
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Figure 2.3: Cumulative Incidence Comparison for AF Based on Original Data and
Imputed Data (Using the mean of intensity estimates) Corresponding to m =5, 20
and 100. Note: The lines for m=5 and 20 are almost overlapped.
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Table 2.1: Statistical Summary of the Patient Population in the Cardiac Study.
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Table 2.2: Likelihood Contributions Corresponding to Different Observation Types.
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Table 2.3: Coefficients and p-values in Regression Model.
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Table 2.4: AF p-values for Group Effect using Likelihood Ratio Test.

26

Table 2.5: p-values for Group Effect using Likelihood Ratio Test (n=180).
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Table 2.6: p-values for Group Effect using Likelihood Ratio Test (n=240).
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Table 2.7: p-values for Group Effect using Likelihood Ratio Test (n=300).
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CHAPTER 3
ESTIMATING TRANSITION INTENSITY RATE ON INTERVAL
CENSORED DATA USING SEMI-PARAMETRIC WITH EM
ALGORITHM APPROACH

3.1 Introduction
3.1.1 Background
Cancer is among one of the leading causes of death in children. In fact, it is the
second leading cause of death just after accidents in children ages 1 to 14. According to the American Cancer Society, approximately 10,500 children under the age
of 15 will be diagnosed with cancer in 2021, and that number is just in the United
States alone. Globally more than 400,000 children are diagnosed with cancer every
year. Though childhood cancer rates have been rising for the past few decades, fortunately, with significant advancements in treatment, survival rates have dramatically
increased. Recent statistics showed that the 5-year survival rate for children is 84%
compared to only 58% in the mid-70s (American Cancer Society). However, this encouraging news comes with some disappointment, that is, childhood cancer survivors
are often at a higher risk of developing late adverse effects, or even mortality, during their adulthood. It is unfortunate that these children who have already suffered
through treatments in their childhood may encounter more suffering as long term
sequalae to their cancer or its treatment. With the increasing number of childhood
cancer survivors worldwide, monitoring for long-term treatment effects is crucial. In
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that context Phase IV clinical trials, such as St. Jude Lifetime Cohort Study, play
an important role in understanding the extent of the long-term complications of the
treatment effect and the risk factors associated with them. Additionally, the insight
gained from these studies could provide valuable information that could be used to
improve the future treatment plans.
Among childhood cancer survivors, cardiovascular events are among the top
nonmalignant causes of death (Armstrong et al., 2009). This is due to the damage to
cardiomyocytes caused by chemotherapy and chest radiation therapy received during
the cancer treatment (Lipshultz et al., 2013). Even though certain chemotherapy such
as anthracycline are well known for its cardiotoxic (Hudson et al., 2007), it remains
a regularly used component of the treatment because of its therapeutic benefits. It
is important to mention that cardiotoxicity is irreversible but preventable. However,
the timing of the intervention is crucial because the therapy itself may be toxic. This
motivates us to estimate the cumulative incidence of the cardiotoxicity in childhood
cancer survivors because such information could be used to help researchers identify
the best time to intervene. More information regarding the causes, treatment, and
prevention of cardiotoxicity can be found in a comprehensive review by Koutsoukis
et al. (2018).
Since it is not practical to follow the survivor continuously in real time in
the long-term follow-up studies because of financial and logistical reasons, the exact
time of cardiotoxicity is, often, not known. However, health related information is
obtained through cross-sectional surveys or when survivors came back to the hospital
and get evaluated periodically, in a fixed time interval (every month or every year)
or in an ad hoc manner. Although the exact time of cardiotoxicity is unknown, the
current status information is available and from there we know that the cardiotoxicity
occurred sometime in the interval between the two follow-up visits. Such dataset can
be characterized as case I interval censored data (Sun, 2006; Rai, 2008).
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3.1.2 Methodology Review
The analysis of interval censored data has been widely discussed. Ayer et al. (1955)
and van Eeden (1956, 1957) first introduced the nonparametric procedures for deriving maximum likelihood estimators. More recently, Sun (2006) discussed a more
comprehensive way of analyzing interval censored data using a nonparametric approach. In semiparametric settings, Huang (1995, 1996) discussed and established
the normality of maximum likelihood estimator. More recently, Goetghebeur and
Ryan (2000) proposed a semiparametric approach to the proportional hazards regression analysis of interval censored data. In terms of parametric settings, Rai et
al. (2013) first introduced a piecewise exponential model for handling current status
data. Later, Srivastava et al. (2018) proposed using Weibull distribution to overcome
the limitation that existed in the piecewise exponential and found it to be more robust. Pradhan and Kundu (2014) also used Weibull distribution as the underlying
lifetime distribution for the interval censored data, but suggested using EM algorithm
approach.
The prevalence of events can be estimated easily from the interval censored
data, but that does not provide useful information. Rather, the incidence rate should
be calculated since every subject is followed with different lengths of time. Both Rai
et al. (2013) and Srivastava et al. (2018) used parametric approach with the assumption that the transition intensity rates from different risk groups are independent. It
is true that subjects in different groups are independent but the rates can be modeled
as dependent in certain way. In other words, the parametric approach may not be
suitable if the underlying parametric assumptions do not hold. We have the same
interest as Rai et al. (2013) and Srivastava et al. (2018), but focusing on using a
semi-parametric approach with EM algorithm. Rai and Matthews (1997) introduced
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the discrete scale models for estimating transition intensity rate in a survival-sacrifice
experiment using EM algorithm. Later, Rai, Matthews and Krewski (2000) extended
the similar methodology to a mixed-scale model with an EM algorithm approach as
well.
EM algorithm is a powerful procedure to use when no closed form solution can
be obtained from the likelihood function. Besides from the traditional EM algorithm,
Rai and Matthews (1993) introduced a modified approach that could potentially
save time (less iterations). A detailed application demonstration of EM algorithm
can be found in Gunaratnam and Rai (2019). Additionally, when dealing with highdimensional parameters, regular simple case likelihood function will not work. Rather,
the use of profile likelihood should be considered (Murphy and Van Der Vaart, 2000).
The details of the approach will be discussed in the next few sections.

3.1.3 Motivating Example
This research was motivated by St. Jude Lifetime Cohort Study (Hudson et al.,
2011). The study was initiated in 2007 and is an ongoing retrospective cohort with
prospective follow-up, which can be classified as a Phase IV study. The objective of
the study is to establish a cohort of childhood cancer survivors, who were treated at
St. Jude and have survived 5 years or more after cancer diagnosis, to better understand the long term sequalae of the cancer and its treatment. SJLIFE participants
fill our detailed questionnaires and undergo comprehensive medical evaluations on a
regular basis. Due to the nature of the study the patient can enter the cohort with
highly variable length of follow-up from cancer diagnosis and the follow-up times after
entering the cohort also may be highly variable. One of the long-term consequences of
cancer patients treated with cardiotoxic therapy (treated with anthracycline and/or
chest radiation) are at a very risk of developing cardiac abnormalities such as abnor-
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mal EF (Ejection Fraction) or abnormal SVR (Systemic Vascular Resistance). Let
us denote this group as AR (At Risk group), and let NR represent the groups of survivors who were not treated with cardiotoxic therapy. Within this context it would
be important to know the timing of the onset of these cardiotoxicities so that timely
interventions could be implemented. That is, we are interested in estimating the CI
of the cardiac events. However, given that the data on cardiotoxicity is collected
intermittently the occurrence of the events falls in the category of interval censored
data discussed above. The focus of this manuscript is to develop a statistical approach that would be able to estimate the CI of cardiac abnormality using interval
censored data. The purpose of using a SJLIFE cohort is to illustrate the usefulness
of the proposed methodology in estimating the CI and should not be used to draw
any clinical conclusions. To better understand the problem at hand, let us define
Year 1 as 5 years after treatment completion and Year 2 as 6 years after treatment
completion, a patient can choose to participate in the study either at Year 1 or Year
2, or even later. The challenge comes when we build the likelihood functions that will
be discussed in the next section.
To help better understand the process, the following table is created to reflect
the data characteristics in a complete data setting. The following table would corespond to survivors who have come for SJLIFE evaluations for the first time and the
maximum follow-up time is 8 years afterr cohort study.
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It is assumed that we are interested in looking at intensity rates up to eight years.
Let λ1i , i = 1, 2, ..., 8 be the intensity rates at every year (Year 1, Year 2, etc.). Let
r+i , i = 1, 2, ..., 8 be the number of subjects that come to the clinic every year. For
example, r+1 patients come to the clinic with 1 year of followup, and r+2 patients
come to the clinic with 2 years of followup. Within each year, there are n events
(patients are abnormal). However, when a patient comes at Year 2, he/she may
become abnormal either in Year 1 or in Year 2, but that information is unknown.
Therefore, we define n12 + n22 as the total number of events in Year 2 in which n12
represent the events that occurred during Year 1 and n22 represent the events that
occurred during Year 2.

3.2 Method
3.2.1 Overall Flow of the Analysis
We prepared the following flow chart to clearly show the steps of the analysis.
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We now carry out the detailed steps in the next section as illustrated in the chart
above.

3.2.2 Detailed Steps of the Analysis
The likelihood function should include all characteristics of the data set. This is
somehow challenging in our situation. Here we present a likelihood approach that we
believe is the best fit of the data. For simplicity purposes, we will only show time up
to three years.
We define the table above as a complete data since we know specifically what
each n is. For incomplete data, we define {(r+k , n+k ), k = 1, 2, 3, · · · , M } and n+k =
Pk
j=1 njk , k = 1, 2, 3, · · · , M . In our case, we can write as n+1 = n11 , n+2 = n12 +
n22 , n+3 = n13 + n23 + n33 . In the incomplete data setting, we only know n+k but
not the component within it.
Since we have two groups, AR and NR, we first define the likelihood function for each
group. The likelihood functions for both groups have the similar form.
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Let

z+j = r+j − n+j , j = 1, 2, 3
p+1 = λ11
p+2 = λ11 + (1 − λ11 )λ12
p+3 = λ11 + (1 − λ11 )λ12 + (1 − λ11 )(1 − λ12 )λ13
p+j

j−1 k
X
Y
= λ11 +
[ (1 − λ1i )]λ1(k+1) , j = 1, 2, 3, ...
k=1 i=1

For incomplete data, let the likelihood functions of the first three time points be:
n

n

L1 = p+1+1 (1 − p+1 )z+1 = λ11+1 (1 − λ11 )r+1 −n+1
n

L2 = p+2+2 (1 − p+2 )z+2 = [λ11 + (1 − λ11 )λ12 ]n+2 [(1 − λ11 )(1 − λ12 )]r+2 −n+2
n

L3 = p+3+3 (1 − p+3 )z+3
= [λ11 + (1 − λ11 )λ12 + (1 − λ11 )(1 − λ12 )λ13 ]n+3 [(1 − λ11 )(1 − λ12 )(1 − λ13 )]r+3 −n+3 .

The generalized form of the likelihood function at each time point can be written as:

Lj = [λ11 +

j−1 k
j
X
Y
Y
(1 − λ1i )λ1(k+1) ]n+j [ (1 − λ1j )]z+j , j = 1, 2, ...
k=1 i=1

k=1

37

For complete data, assume the number of events follows a multinomial distribution.
Let the likelihood functions of the first three time points be:

L1 = λn1111 (1 − λ11 )z+1
L2 = λn1112 [(1 − λ11 )λ12 ]n22 [(1 − λ11 )(1 − λ12 )]z+2
L3 = λn1113 [(1 − λ11 )λ12 ]n23 [(1 − λ11 )(1 − λ12 )λ13 ]n33 [(1 − λ11 )(1 − λ12 )(1 − λ13 )]z+3 .

The generalized form of the likelihood function at each time point can be written as:

Lj =

n
λ111j [(1

− λ11 )λ12 ]

n2j

···[

j−1
Y

(1 − λ1k )λ1j ]

njj

k=1

j
Y

(1 − λ1k )z+j

k=1

We denote λ1k the intensity rate for AR group, and λ∗1k the intensity rate for NR
group.
For AR group, the likelihood function is:

LAR =

M
Y

PM

j=1

Lk = λ11

n1j

PM

λ12

j=2

n2j

PM

· · · λ1kj=k

nkj

MM
· · · λn1M

k=1
PM

PM

P
nkj + M
j=1 z+j )

PM

PM

P
nkj + M
j=2 z+j )

PM

PM

P
nkj + M
j=3 z+j )

×(1 − λ11 )(

k=2

×(1 − λ12 )(

k=3

×(1 − λ13 )(

k=4

j=k

j=k

j=k

× · · · (1 − λ1,M −1 )nM M +zM −1 +zM (1 − λ1M )z+M

=

M
Y

PM

{λ1kj=k

nkj

PM

(1 − λ1k )(

k=1
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i=k+1

PM

j=i

nij +

PM

j=k z+j )

}

Similarly, for NR group the likelihood function is:

LN R =

M
Y

L∗k

=

k=1

M
Y

P
∗ M
n∗
{λ1k j=k kj (1
k=1

PM

− λ∗1k )(

i=k+1

PM

j=i

P
∗
n∗ij + M
j=k z+j )

}

The log-likelihood function for the entire population would simply be the sum
of logLAR and logLN R .
λ1k and λ∗1k can be modeled as dependent using certain relationship so that
both transition intensity rates can be included in one model. In addition, by establishing a relationship, we can replace one term with the other, which could potentially
reduce the number of parameters in the calculation.
Assume there is a logit relationship between both group’s transition intensity
rates, defined as eβ , that is:

λ∗1k =

1 − λ1k
eβ λ1k
∗
,
1
−
λ
=
1k
1 + (eβ − 1)λ1k
1 + (eβ − 1)λ1k

To derive the full complete log-likelihood function, we replace both λ∗1k and
1 − λ∗1k with terms above.
The full complete log-likelihood can be written as follow (denote θ = (λ, β)):
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lc (λ, β) = lc (θ) =

M
M
M X
M
M
X
X
X
X
{(
nkj )logλ1k + (
nij +
z+j )log(1 − λ1k )}
k=1

i=k+1 j=i

j=k

j=k

M X
M
X
+
[
n∗kj {β + logλ1k − log[1 + (eβ − 1)λ1k ]}
k=1 j=k

+(

M X
M
X

n∗ij +

M
X

i=k+1 j=i

=

M X
M
X

∗
)(log(1 − λ1k ) − log[1 + (eβ − 1)λ1k ])]
z+j

j=k

(nkj + n∗kj )logλ1k

k=1 j=k

+

M
M X
M
M
X
X
X
∗
(
(nij + n∗ij ) +
(z+j + z+j
))log(1 − λ1k )
k=1 i=k+1 j=i

j=k

M X
M
M X
M
M
X
X
X
∗
∗
∗
−
(
nkj +
nij +
z+j
)log(1 + (eβ − 1)λ1k )
i=k+1 j=i

k=1 j=k

+

M X
M
X

j=k

n∗kj β

(3.1)

k=1 j=k

From the equation above we can obtain the sufficient statistics as follow:

⇒

M
X
j=k

(nkj +

n∗kj ),

M
X

n∗kj (k = 1, 2, ..., M )

j=k

We assume n+j is known in the incomplete data and follows a binomial distribution.
We can then estimate the distribution of nkj . We calculate the condition distribution
based on the incomplete likelihood function.
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That is, n+j ∼ B(r+j , 1 −

Qj

i=1 (1

− λ1i )), j = 1, 2, ..., M

⇒ n+j =

j
X

nkj

k=1

⇒ nkj |n+j

Qk−1
(1 − λ1i )λ1k
∼ B(n+j , i=1Qj
), k = 1, 2, ..., j, j = 1, 2, ..., M.
1 − i=1 (1 − λ1i )

We can also obtain the expected value.
Q
λ1k n+j k−1
(1 − λ1i )
E(nkj |n+j ) =
Qj i=1
[1 − i=1 (1 − λ1i )]
E(n∗kj |n∗+j )

Q
∗
λ∗1k n∗+j k−1
i=1 (1 − λ1i )
=
Qj
[1 − i=1 (1 − λ∗1i )]

For simplicity, let
t(k) =

M
X

(nkj + n∗kj );

j=k

t = (t(1), ..., t(M ))T
We denote N = {n+k , k = 1, 2, ..., M }, N ∗ = {n∗+k , k = 1, 2, ..., M }.
Since
j−1
Y
(n1j , n2j , · · · , njj ) ∼ M ulti(r+j , λ11 , (1 − λ11 )λ12 , (1 − λ11 )(1 − λ12 )λ13 , · · · , (1 − λ1i ) × λ1j )
i=1

⇒ nkj ∼ B(r+j ,

k−1
Y

(1 − λ1i ) × λ1k )

i=1
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By applying EM Algorithm, we have the following two steps:
E-step:

∆

∗

Gk (λ, β) = E(t(k)|N, N ) = E(

M
X

M
X
nkj |N ) + E(
n∗kj |N ∗ )

j=k

=

M
X

j=k

E(nkj |n+j ) +

j=k

=

M
X
j=k

+

M
X

E(n∗kj |n∗+j )

j=k

k−1

Y
n+j
×
(1 − λ1i ) × λ1k
Qj
1 − i=1 (1 − λ1i ) i=1

M
X
j=k

n∗+j
1−

Qj

i=1 (1

−

λ∗1i )

×

k−1
Y

(1 − λ∗1i ) × λ∗1k

i=1

t(0) = (t(0) (1), · · · , t(0) (M ))T
t(0) can be obtained by insert β(0) and λ(0) (initial values) into the function.
t(0) (k) = Gk (λ, β)|λ = λ(0) , β = β(0)

M-step:
M
X
(Enkj + En∗kj )
Hk (λ, β) = E(t(k)) =
∆

j=k

=

k−1
Y

M
X

i=1

j=k

(1 − λ1i ) × λ1k ×

r+j +

k−1
M
X
X
∗
r+j
(1 − λ∗1i )λ∗1k
i=1

j=k

Based on EM algorithm, we can obtain the values of λ(m) and β (m) . From there we
can then generate the values of λ(m+1) and β ((m+1) .

⇒ Gk (λ(m) , β (m) ) = Hk (λ(m+1) , β (m+1) )
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⇒

k−1
Y

(1 −

(m+1)
λ1i
)

×

(m+1)
λ1k

i=1

=

+

r+j

k−1
M
X
X
∗(m+1) ∗(m+1)
∗
+
(1 − λ1i
)λ1k
r+j
i=1

j=k

n+j

k−1
Y

i=1 (1

(m)
λ1i ) i=1

M
X
j=k

M
X

1−

Qj

M
X
j=k

−

n∗+j
1−

Qj

i=1 (1

−

∗(m)
λ1i )

j=k

(m)

(m)

(1 − λ1i ) × λ1k

×

k−1
Y

∗(m)

∗(m)

(1 − λ1i ) × λ1k ), k = 1, 2, · · · , M (3.2)

i=1

where
∗(m)

λ1k

=

eβ

(m)

∗(m)

λ1k

(m)

1 + (eβ (m) − 1)λ1k

λ and β are now obtained.

3.3 Simulation Studies
3.3.1 Simulation Steps
We define the true λ and β values and apply the method discussed in the last section
to see how close the simulated values compared to the true values.
For simplification purpose, the simulation only considers three time points. The simulation is carrying out using the following steps:

(0)

(0)

(0)

1. Define initial values: λ11 , λ12 , λ13 and β.

(1)

2. Compute λ1k and β (1) . In profile likelihood we assume β is known.

(0)

(0)

i. Insert λ1k into equation (3.1) to get lc (λ(0) , β) = λc (β)
By taking the derivative of the above equation with respect to beta and set to
zero, we can solve for β (1) .
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(0)

That is

∂lc (β)
∂β

= 0 ⇒ β (1)

ii. Insert β (0) and λ0) into equation (3.2), we have
(1)

Gk (λ(0) , β (0) ) = Hk (λ(1) , β (0) ) ⇒ λ1k , k = 1, 2, 3.
(m)

3. mth iteration: compute λ1

(m−1)

i. Insert λ1k

and β (m) .

(m−1)

into equation (3.1) to get lc (λ1

(m−1)

, β) = λc

(β)

By taking the derivative of the above equation with respect to beta and set to
zero, we can solve for β (m) .
(m−1)

That is

∂lc

(β)

∂β

(m−1)

ii. Insert λ1k

= 0 ⇒ β (m)

and β (m−1) into equation (3.2), we have
(m)

Gk (λ(m−1) , β (m−1) ) = Hk (λ(m) , β (m−1) ) ⇒ λ1k , k = 1, 2, 3.
(m)

(m)

(m)

(m−1)

4. If the distance between (λ11 , λ12 , λ13 , β (m) ) and (λ11

(m−1)

, λ12

(m−1)

, λ13

, β (m−1) )

(m)
is smaller than a pre-selected C0 , we stop the iteration and report λˆ1k = λ1k , (k =

1, 2, 3) and β̂ = β (m) .
We can then use these two values to get λˆ∗1k .
⇒ λˆ∗1k =

λˆ1k eβ̂
1 + (eβ̂ − 1)λˆ1k

, k = 1, 2, 3.

3.3.2 Simulation Results
We calculated λ and β with different sample size assumptions. In reality, we assume
the number of subjects is always larger in the AR group compared to the NR group.
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We also tested for equal sample size just for demonstration purposes.
Simulated results can be found in Table 3.1. The values of simulated β are very
close to the true β value which suggests that the relationship between two groups’
transition intensity rates have maintained through the simulation. Regardless the
size or the ratio of the sample sizes, all simulated values tend to converge to the true
value. Visualized results can be found in Figure 3.1 (for AR group) and Figure 3.2
(for NR group).
We also report the confidence intervals, IQR, as well as standard deviation
(Table 3.2). The confidence intervals are calculated based on mean and standard
error while the IQR are calculated from 25% and 75% quantile.

3.4 Discussion
In this project, we applied the EM algorithm with the profile likelihood for estimating
transition intensity rate under the semi-parametric setting. We employed a logit relationship between transition intensity rates from different risk groups. The data-driven
likelihood function includes almost all the characteristics of the dataset. Though for
demonstration purposes we only considered a few time points, one could easily apply
the approach to a much larger dataset. By employing proposed approach, one could
also save time during calculation due to the reduction of parameters.
When the dataset has a small sample size, one could combine time points together and estimate the transition intensity rates. If the sample size is large, yearly
rates should be considered as described in this project.
The relationship between λ and λ∗ is extremely important. Here we assume
a logit relationship based on Cox’s proportional model (Cox, 1972), but other approaches can also be considered. For example, one could consider using λ = λ∗ + γ
which is called an additive failure rate approach in Rai and Matthews (1997). We did
not consider the rate dependent on the exponential distribution as Rai et al. (2013)
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did. However, one could easily extend the methodology to include piecewise exponential.
For simplification purposes the methodology is built upon a special case twostate model. Future research will extend the methodology to a complete three-state
model, which in that case, more parameters will be included.
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3.5 Tables and Figures
Figure 3.1: Corresponding λ values with different sample size assumptions (AR
group).
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Figure 3.2: Corresponding λ values with different sample size assumptions (NR
group).
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Table 3.1: Comparison of simulated mean λ and β values with the true value.
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Table 3.2: Confidence intervals, interquartile range, and standard deviations for λ
and β with different sample size.
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CHAPTER 4
ESTIMATING CUMULATIVE INCIDENCE RATE ON INTERVAL
CENSORED DATA IN AN ILLNESS-DEATH MODEL

4.1 Introduction
4.1.1 Background
In the first project, we discussed about the issue of missing information on interval
censored data. We proposed an imputation approach to overcome the issue, and
through simulation, we concluded that the imputed data was much efficient than the
one without. In the second project, we proposed a new approach to estimate the
transition intensity probabilities on interval censored data in an illness/death model.
We established a logit relationship between transition intensity rates, obtained from
each risk group respectfully. We later applied the EM algorithm with profile likelihood to obtain the final outcome. Simulation studies also prove that the approach is
valid since the true value and simulated values were very close.
However, proposed approaches in both projects are built upon a special case
illness/death model which no death has occurred. In that case, we only have event
cases (patients with abnormality) and censored cases. The special case two-state
model provides us the convenience to validate our methodologies with the option to
easily extend to a complete three-state model.
Regardless of the model, our primary interest is still λ1 , the transition intensity rate for patients progressing towards cardiac abnormal. However, the situation
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is getting a little bit more complicated when some patients progress from the initial
state directly to the absorbing state, which is λ3 on Figure 1.1. This is known as the
competing risk events of λ1 .
In this project, we will be estimating λ1 incorporating information from both
λ2 and λ3 . With additional information included, the result is expected to be more
accurate. We will be carrying out both parametric approach, as described in Rai et al.
(2013), and semi-parametric approach, as described in the second project. However,
in this dissertation we will only show the parametric approach. The semi-parametric
approach can be later found in a published article.

4.1.2 Methodology Review
In longitudinal failure time data, multi-state models are among the mostly used models when examining the event outcomes. Commegenes (2002) provided an overview
of the inference for nonparametric approaches for the multi-state model. Ruiz-Castro
and Zenga (2020) discussed the use of a general piecewise multi-state survival model.
The illness-death model is one of the simple cases of the multi-state model. R packages
such as TP.idm can be used to estimate the transition probabilities in an illness-death
model through a nonparametric approach (Balboa and Una-Alvarez, 2018).
Competing risk does not become a neglected topic in survival analysis. When
competing events occur, basic Kaplan-Meier estimation procedure is not usually applicable as it is unable to account for the information passed from the competing
events. In time-to-event data, Stagopan et al. (2004) introduced a nonparametric
approach incorporating competing risk and compared with Kaplan-Meier estimation
approach and found that failing to account for competing events might lead to an
overestimation of the cumulative incidence.
Under the interval censored competing risk data, Kim and Kim (2016) dis-
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cussed the analysis by using a pseudo-value approach and found it performed well
under various scenarios. Mao et al. (2017) introduced a semi-parametric approach
for handling such dataset. Mostly recently, Park et al. (2021) developed a comprehensive analysis of interval censored data with competing events and missing events.
R package such as intccr has been developed and can be easily used to handle such
data (Park et al., 2019). In the illness-death model, Hinchliffe et al. (2013) presented
the theory of using a flexible parametric survival model approach. More information
regarding mutli-state models for interval censored data can be found in van den Hout
(2020).

4.2 Method
The parametric method used in this project is an extension from Rai et al. (2013).
Detailed approach of getting the likelihood function can be found in Appendix 1.
After getting the full likelihood function, we calculate the score function and the
information matrix.
Let λ be the vector of λ1 , λ2 , λ3 .
The score function can be defined as:

S(λ) = (

∂l ∂l ∂l T
,
,
)
∂λ1 ∂λ2 ∂λ3

The information matrix can be defined as:
X
∂ 2l
)3×3
(λ) = (
∂λi ∂λj
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Detailed derivations and final form of their components can be found in Appendix 2.
Through Newton-Raphson method, we can obtain λ using the following formula:

⇒ λ(p+1) = λ(p) − s(p)

X

(λ(p) )S(λ(p) ), (0 < s(p) ≤ 1)

where s(p) is a coefficient between 0 and 1. The purpose of this term, known as the
restraint coefficient for the Newton-Raphson method, is to make sure the second part
of the function does not exceed 1.
The semi-parametric method is a modified updated version of the one that was
introduced in the second project. Detailed approach and application will be available
in a future published manuscript.

4.3 Data Application
4.3.1 Data Information
In the previous two projects, the group classification (AR or NR) was defined based
on variables AF and FS. In the updated dataset, in addition to these two variables,
we include two new measurements: systemic vascular resistance (SVR) and ejection
fraction (EF). Based on experienced physicians’ point of view, SVR and EF are more
suitable for determining the cardiac condition of patients and both measurements are
more often used in the real clinical setting.
SVR is the calculated amount of force for left ventricular afterload. It represents the resistance in the circulatory system that is used to pump and circulate blood
(Abbas et al., 2004; Almodovar et al., 2011). According to the American Society of
Echocardiography’s guidelines and standards, SVR can be calculated by using the
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following formula:

SV R (dynes × sec/cm5 ) =

M AP − RAP (mm Hg)
× 80
CO (L/min)

where M AP represents the mean arterial pressure, RAP represents the mean right
atrial pressure, and CO represents the cardiac output (Porter et al., 2015). The normal range for SVR is between 900 and 1440.
EF is a measurement of the percentage of blood pumped out from the left
ventricle at each contraction (Mayo Clinic, accessed on March 16, 2021). According
to the American Heart Association, the normal range of EF is between 50% and 75%.
The distribution of the dataset can be found in the table below.

Notice that in the NR group, death cases in both normal and abnormal patients are
relatively small.

4.3.2 Application Result
Note that the primary purpose of this data application is to demonstrate statistical
methods and to show the importance of estimating cumulative incidence rates, readers
should not draw clinical conclusions from this project.
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We obtained all three transition intensity rates (λ1 , λ2 and λ3 ) though our
primary interest is λ1 . The transition intensity rate for the AR group is 0.0143.
Similarly, the NR group has the transition intensity rate of 0.0096 (Table 4.1). Group
effect appears to be significantly different with p-value less than 0.001. The rate for
AR is greater than NR proves the assumption that the incidence rate is much higher
for patients treated with cardiac radiation or anthracycline.
As noted before, the transition intensity rate alone cannot produce valuable
information to the researchers. Reporting the cumulative incidence rate is more ideal.
Here we report the fixed-term cumulative incidence rate based on λ1 (Table 4.2). By
five years, the difference in cumulative incidence rates tend to be small (2% difference).
This suggests that at the beginning of the followup, intervention might not be needed
since AR and NR groups have similar cumulative incidence rates. However, when
the patients reach Year 10, the difference is a little bit over 5%, and by Year 20,
the difference is approximately 10%. This suggests that somewhere in between, an
intervention should be considered. The visualized plot can be found in Figure 4.1.

4.4 Discussion
In this project we applied parametric and semi-parametric methods on a new dataset
in a three-state illness/death model. The new dataset actually has more than 4000
observations, but we only managed to use less than half of it. The issue is similar to
the one that was described in the first project. To declare whether or not a patient
is cardiac abnormal, several outcome variables can be used. For ejection fraction, it
is just one single variable, but for SVR, it is calculated from three different measurements. If one of these measurements is not available for any unspecified reason, then
we are not able to calculate SVR, and therefore, we could not determine the patient’s
heart condition. Even if the patient has a normal AF value, we cannot assume that
the SVR is normal as well. Correlation tests need to be carried out to see if these
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variables are in fact related. Afterwards, proper imputation, as discussed in the first
project, should be taken to avoid the loss of valuable information.
Similar issues might also impact the distribution of the data as well as the outcome. In our dataset, the ratio of two risk groups tends to be large. This can be true
because most cancer patients were treated with cardiac radiation or anthracycline,
but it also might be caused by the missing observations. In the NR group, death cases
are very few. This is either because the NR group patients are more likely to live
longer, or because there are missing observations we did not include in the analysis.
Valuable information is in fact lost. There are several literature discussions about the
analysis on interval censored competing risk data with missing information. Lee and
Kim (2018) and Li, Luderer, and Baker (2014) proposed using imputation to handle
such issues. Mitra, Das and Das (2019) proposed an approach that utilizes available
data to analyze the interval censored competing risk data.
In the parametric setting, we assume the rate follows an exponential distribution which means the rate is constant at all time points. Though it is much easier to
calculate because the number of parameters is much smaller, this assumption might
not always be true. As a result, we suggest using a semi-parametric approach to
obtain a more accurate outcome.
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4.5 Tables and Figures
Figure 4.1: Fixed-term cumulative incidence rates for AR and NR groups (λ1 ).
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Table 4.1: Transition intensity rates for AR and NR groups.
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Table 4.2: Fixed-term cumulative incidence rates for AR and NR groups.
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FUTURE WORK
We have established the fundamental theory of analyzing interval censored data in
an illness/death model, specifically for childhood cancer survivors treated with chest
radiation or anthracycline. With additional information (variables) on hand, we can
incorporate each of them into the model to help improve the accuracy of the outcome.
We believe that, by estimating the cumulative incidence rates, physicians could gain
insightful knowledge of their patients as well as the treatments they received. In
future works, we will incorporate comorbidity information into the model. We will
also use measurements from multi-visits to create a longitudinal model. Last but not
the least, we will develop a modified model to incorporate gene expression data. With
better estimation, cardiotoxicity can be prevented and lives can be saved.
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APPENDIX

Appendix 1: Detailed likelihood approach in a three-state model.
We adapt the following information from Rai et al. (2013).
From Figure 1.1, we define four likelihood functions corresponding with different
scenario.
Death with No Cardiac Abnormality:

L1 (t) = λ2 (t)Q(t) = λ2 e−(λ1 +λ2 )t

Alive with No Cardiac Abnormality:

L2 (t) = Q(t) = e−(λ1 +λ2 )t

Death/Cardiac Failure with Cardiac Abnormality:
Z

t

λ1 e−(λ1 +λ2 )u λ3 e−λ3 (t−u) du =

L3 (t) =
0

λ1 λ3
(e−λ3 t − e−(λ1 +λ2 )t )
λ1 + λ2 − λ3

Alive with Cardiac Abnormality:
Z
L4 (t) =

t

λ1 e−(λ1 +λ2 )u e−λ3 (t−u) du =

0

71

λ1
(e−λ3 t − e−(λ1 +λ2 )t )
λ1 + λ2 − λ3

The complete log-likelihood function can be calculated as

l(λ1 , λ2 , λ3 ) =

n
X

[ai logL1 (ti ) + bi logL2 (ti ) + ci logL3 (ti ) + di logL4 (ti )]

i=1

=

n
X

ai [logλ2 − (λ1 + λ2 )ti ] −

i=1

+

n
X

bi (λ1 + λ2 )ti

i=1

n
X

ci [logλ1 + logλ3 − log(λ1 + λ2 − λ3 ) + log(e−λ3 ti − e−(λ1 +λ2 )ti )]

i=1

+

n
X

di [logλ1 − log(λ1 + λ2 − λ3 ) + log(e−λ3 ti − e−(λ1 +λ2 )ti )]

i=1

where ai = δi (1 − γi ), bi = (1 − δi )(1 − γi ), ci = δi γi , di = (1 − δi )γi are the indicators
corresponding to observation type 1 to type 4.
We define
δi =




1 if subject i dead or cardiac failure at time ti


0 if subject i alive no cardiac failure at time ti

and
γi =




1 if subject i with abnormal value at time ti


0 if subject i with normal value at time ti

To help further simplify the equation, we define:

D1 =

n
X

ai , D 2 =

i=1

T1 =

n
X

n
X

bi , D3 =

i=1

n
X

ci , D 4 =

i=1

(ai + bi + ci + di )ti , T2 =

i=1

di

i=1
n
X
i=1
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n
X

(ai + bi )ti

Appendix 2: Derivation of components in the score function and information matrix.

n

X
∂l
1
1
(ci + di )ti
= −T2 + ( −
)(D3 + D4 ) +
∂λ1
λ1 λ1 + λ2 − λ3
e(λ1 +λ2 −λ3 )ti − 1
i=1
n

X
D1
D3 + D4
(ci + di )ti
∂l
)+
=
− T2 −
(λ
∂λ2
λ2
λ1 + λ2 − λ3
e 1 +λ2 −λ3 )ti − 1
i=1
n

X (ci + di )ti
1
1
D4
∂l
=( +
)D3 +
−
∂λ3
λ3 λ1 + λ2 − λ3
λ1 + λ2 − λ3
1 − eλ1 +λ2 −λ3 )ti
i=1
n

X
D3
D3 + D4
(ci + di )ti
=
+
− T1 + T2 −
(λ
1
λ3
λ1 + λ2 − λ3
e +λ2 −λ3 )ti − 1
i=1
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
∂ 2l
1
1
i
=(
− 2 )(D3 + D4 ) −
2
2
(λ
+λ
−λ3 )ti − 1)2
1
2
∂λ1
(λ1 + λ2 − λ3 )
λ1
(e
i=1
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
D3 + D4
∂l
i
=
−
(λ1 +λ2 −λ3 )ti − 1)2
∂λ1 ∂λ2
(λ1 + λ2 − λ3 )2
(e
i=1
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
∂l
D3 + D4
i
=−
+
∂λ1 ∂λ3
(λ1 + λ2 − λ3 )2 i=1 (e(λ1 +λ2 −λ3 )ti − 1)2
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
∂ 2l
−D1
D3 + D4
i
=
+
−
(λ1 +λ2 −λ3 )ti − 1)2
∂λ22
λ22
(λ1 + λ2 − λ3 )2
(e
i=1
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
∂l
D3 + D4
i
=−
+
2
(λ
+λ
−λ3 )ti − 1)2
1
2
∂λ2 ∂λ3
(λ1 + λ2 − λ3 )
(e
i=1
n

X (ci + di )t2 e(λ1 +λ2 −λ3 )ti
∂ 2l
−D3
D3 + D4
i
= 2 +
−
2
2
(λ
+λ
−λ3 )ti − 1)2
1
2
∂λ3
λ3
(λ1 + λ2 − λ3 )
(e
i=1
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